PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – December 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Jan. 6, 2017-- Regulatory News : Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website :
View HTML
Toggle Summary ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium
LYON, France --(BUSINESS WIRE)--Jan. 17, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs
View HTML
Toggle Summary ERYTECH to Hold Business Update and 2016 Financial Results Conference Call on March 3rd, 2017
LYON, France --(BUSINESS WIRE)--Feb. 28, 2017-- Regulatory News : ERYTECH (Paris:ERYP) (ADR:EYRYY) :, the clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for Full Year 2016
Conference call and webcast on Friday, March 3rd at 15:00 pm CET / 09:00 am EST Activities for resubmission of European Marketing Authorization Application (MAA) for eryaspase (GRASPA) in relapsed and refractory acute lymphoblastic leukemia (ALL)ongoing after withdrawal in November 2016 ;
View HTML
Toggle Summary ERYTECH to Present Preclinical Results Supporting Immunotherapy Potential of ERYMMUNE Platform at Two Upcoming Medical Meetings
LYON, France --(BUSINESS WIRE)--Mar. 7, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating
View HTML
Toggle Summary ERYTECH Presents New Preclinical Anti-Tumor Data on Erymethionase at AACR 2017
LYON, France --(BUSINESS WIRE)--Mar. 20, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating
View HTML
Toggle Summary ERYTECH Collaborates with Fox Chase Cancer Center to Advance Its Platform in the Field of Rare Metabolic Disorders
LYON, France --(BUSINESS WIRE)--Mar. 23, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into
View HTML
Toggle Summary ERYTECH Reports Positive Phase 2b Data for eryaspase for the Treatment of Metastatic Pancreatic Cancer
Conference call and webcast on Tuesday, March 28 th at 14:30 pm CET / 08:30 am EDT Primary progression-free survival (PFS) and overall survival (OS) endpoints met in patients with low asparagine synthetase (ASNS) Statistically significant improvement of OS and PFS in the entire patient population
View HTML
Toggle Summary ERYTECH Makes Its 2016 Reference Document Available
LYON, France --(BUSINESS WIRE)--Apr. 3, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform,
View HTML
Toggle Summary Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – March 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Apr. 4, 2017-- Regulatory News : Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut (1) voting rights   Total of net (2) voting rights 01
View HTML
Top